TY - JOUR
T1 - Functional Delivery of Lipid-Conjugated siRNA by Extracellular Vesicles
AU - O'Loughlin, Aisling J.
AU - Mäger, Imre
AU - de Jong, Olivier G.
AU - Varela, Miguel A.
AU - Schiffelers, Raymond M.
AU - El Andaloussi, Samir
AU - Wood, Matthew J.A.
AU - Vader, Pieter
N1 - Publisher Copyright:
© 2017 The American Society of Gene and Cell Therapy
PY - 2017/7/5
Y1 - 2017/7/5
N2 - Extracellular vesicles (EVs) are cell-derived, membranous nanoparticles that mediate intercellular communication by transferring biomolecules, including proteins and RNA, between cells. As a result of their suggested natural capability to functionally deliver RNA, EVs may be harnessed as therapeutic RNA carriers. One major limitation for their translation to therapeutic use is the lack of an efficient, robust, and scalable method to load EVs with RNA molecules of interest. Here, we evaluated and optimized methods to load EVs with cholesterol-conjugated small interfering RNAs (cc-siRNAs) by systematic evaluation of the influence of key parameters, including incubation time, volume, temperature, and EV:cc-siRNA ratio. EV loading under conditions that resulted in the highest siRNA retention percentage, incubating 15 molecules of cc-siRNA per EV at 37°C for 1 hr in 100 μL, facilitated concentration-dependent silencing of human antigen R (HuR), a therapeutic target in cancer, in EV-treated cells. These results may accelerate the development of EV-based therapeutics.
AB - Extracellular vesicles (EVs) are cell-derived, membranous nanoparticles that mediate intercellular communication by transferring biomolecules, including proteins and RNA, between cells. As a result of their suggested natural capability to functionally deliver RNA, EVs may be harnessed as therapeutic RNA carriers. One major limitation for their translation to therapeutic use is the lack of an efficient, robust, and scalable method to load EVs with RNA molecules of interest. Here, we evaluated and optimized methods to load EVs with cholesterol-conjugated small interfering RNAs (cc-siRNAs) by systematic evaluation of the influence of key parameters, including incubation time, volume, temperature, and EV:cc-siRNA ratio. EV loading under conditions that resulted in the highest siRNA retention percentage, incubating 15 molecules of cc-siRNA per EV at 37°C for 1 hr in 100 μL, facilitated concentration-dependent silencing of human antigen R (HuR), a therapeutic target in cancer, in EV-treated cells. These results may accelerate the development of EV-based therapeutics.
KW - delivery
KW - exosomes
KW - extracellular vesicles
KW - RNA interference
KW - siRNA
UR - http://www.scopus.com/inward/record.url?scp=85017141800&partnerID=8YFLogxK
U2 - 10.1016/j.ymthe.2017.03.021
DO - 10.1016/j.ymthe.2017.03.021
M3 - Article
C2 - 28392161
SN - 1525-0016
VL - 25
SP - 1580
EP - 1587
JO - Molecular Therapy
JF - Molecular Therapy
IS - 7
ER -